Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.
about
Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myelomaAlterations in Salivary Proteome following Single Twenty-Minute Session of Yogic Breathing.Immunoglobulin heavy/light chain analysis enhances the detection of residual disease and monitoring of multiple myeloma patients.Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma.Abnormalities in Chromosomes 1q and 13 Independently Correlate With Factors of Poor Prognosis in Multiple MyelomaThe serological diagnostic challenges of multiple myeloma.Heavy + light chain analysis to assign myeloma response is analogous to the IMWG response criteria.Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma.Risk Stratification in Multiple Myeloma.Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma.Standardisation of minimal residual disease in multiple myeloma.Active multiple myeloma suppresses and typically eliminates coexisting MGUS.Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.Levels of uninvolved immunoglobulins predict clinical status and progression-free survival for multiple myeloma patients.Combined use of free light chain and heavy/light chain ratios allow diagnosis and monitoring of patients with monoclonal gammopathies: Experience of a single institute, with three exemplar case reports.Prognostic value of serum heavy/light chain ratios in patients with POEMS syndrome.The Effect of Suppressed Levels of Uninvolved Immunoglobulins on the Prognosis of Symptomatic Multiple Myeloma.IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma.Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.The serum heavy/light chain immunoassay: A valuable tool for sensitive paraprotein assessment, risk, and disease monitoring in monoclonal gammopathies.The clinical utility of serum free light chain and heavy/light chain assays in monitoring disease activity in patients with IgG myeloma after achieving a deep response.Cytogenetic aberrations in multiple myeloma are associated with shifts in serum immunoglobulin isotypes distribution and levels.Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients.Detection of leukemia markers using long-range surface plasmon waveguides functionalized with Protein G.Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma.
P2860
Q33816012-89A666DB-41DA-4F7D-9991-C8839456D297Q35248962-644B1DD8-0693-4E47-86E3-1D4780A4BD8FQ35847877-52718058-4F3A-421E-B93D-4902657B9E85Q36799760-AB717D65-057A-4836-B4CB-CE5BBF4DA45DQ37231523-7CAE1834-3044-44B3-9B11-9B1C5B74EE0DQ38351789-730A7E61-8943-49D1-869A-05A52E2E517EQ38373226-BC241E25-557A-4C46-92CC-31262DEDA372Q38722312-D639410F-4B08-43D1-9C28-32FB525F84ADQ38736249-7194E0F9-7E12-4B59-8EC1-01208AE1ED78Q38736404-068B3891-F2E2-4D6A-B54C-4AB7F23B03F9Q39410899-BCA405CE-A81C-4FC4-8DDF-771ECFC55D2EQ40114748-4600753F-EABD-4B30-BBC5-1614209B1CA2Q40563598-9112F6A1-3699-4F94-9EF4-5AC6562D21A8Q40831660-B610E285-305B-44F5-A15F-5EFD340E46E8Q41195228-58EF8353-C531-47C3-A116-E8BEBD95CE3FQ41348558-D63A330A-5295-4E02-9DDC-6A29E59A4CA5Q42250752-FE3B1117-0C26-4A54-944D-D885E3AD8330Q44818652-D56189CA-63DB-415C-9A5C-C0D2BBBA8629Q46878801-324CAAAA-9274-47DA-A6D1-2AF3FAED281DQ47679443-90FFDCAB-8911-4BEF-BC84-BCFED465F252Q47833870-CC4E5B0D-BA54-4717-8078-63CC5C6B54A0Q48154938-451F61B0-008E-47CD-BBD8-83BD3317BA99Q50118895-40536EB2-3B56-4AF8-A334-BCCCE565A6CFQ50224356-54D5B96E-CC75-4FA3-876E-97B2DD8ACABDQ50935328-35B7BF25-3BE6-409E-ABF6-726AF71A1DCDQ53093363-E2D1FFE1-C62D-4BBA-90ED-46FF37A62F67
P2860
Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Prognostic utility of intact i ...... in multiple myeloma patients.
@ast
Prognostic utility of intact i ...... in multiple myeloma patients.
@en
type
label
Prognostic utility of intact i ...... in multiple myeloma patients.
@ast
Prognostic utility of intact i ...... in multiple myeloma patients.
@en
prefLabel
Prognostic utility of intact i ...... in multiple myeloma patients.
@ast
Prognostic utility of intact i ...... in multiple myeloma patients.
@en
P2093
P2860
P50
P356
P1433
P1476
Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients
@en
P2093
J-L Harousseau
N Fourrier
P2860
P2888
P304
P356
10.1038/LEU.2012.159
P577
2012-06-13T00:00:00Z